Clinical Trial Update: Spironolactone in the Treatment of Heart Failure [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating spironolactone for heart failure with mid-range or preserved ejection fraction has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Mid-range Ejection Fraction
• Heart Failure with Preserved Ejection Fraction

Drugs mentioned

• Aldactone (spironolactone)

Snippet

Sponsor: Charite University, Berlin, Germany | Conditions: Heart Failure with Mid-range Ejection Fraction, Heart Failure with Preserved Ejection Fraction | Phase 3 | Status: TERMINATED